What is Relmada Therapeutics Inc's earnings per share (EPS)?

Relmada Therapeutics Inc (RLMD) reported diluted earnings per share of $-1.45 for fiscal year 2025. This represents a 45.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Relmada Therapeutics Inc Financials

RLMD

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Relmada Therapeutics Inc (RLMD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI RLMD FY2025 2026-05-12

Relmada’s capital-funded R&D model is becoming leaner, but equity issuance still does the work reported revenue normally would.

After raising $93.6M in FY2025, total liabilities were still only $7.5M, indicating new equity rather than leverage is what keeps the business funded today. That funding came with heavy dilution, as shares outstanding jumped from 30.2M to 73.3M, while operating cash burn still absorbed much of the fresh capital instead of letting cash accumulate.

The improvement since FY2023 looks like a spending reset, not operating scale. R&D fell from $54.8M to $26.9M by FY2025, and SG&A also moved lower, so the narrower operating loss reflects a smaller internal cost base rather than customers beginning to cover it.

Near-term liquidity is not the immediate pressure point. Current assets of $94.0M against current liabilities of $6.4M show a balance sheet built to meet short-term obligations, but with no reported revenue base this remains a financing-dependent development business rather than a self-funding one.

Financial Health Signals

Financial Profile 35/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Relmada Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

100

Relmada Therapeutics Inc carries a low D/E ratio of 0.09, meaning only $0.09 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 14.62, Relmada Therapeutics Inc holds $14.62 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Returns

Relmada Therapeutics Inc generates a 0.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 11/100. This is up from 0.0% the prior year.

Piotroski F-Score Weak

1/9

Relmada Therapeutics Inc passes 1 of 9 financial strength tests. No profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

Relmada Therapeutics Inc reported $0 in net income in fiscal year 2025.

EPS (Diluted)

$-1.45

YoY+45.3%

Relmada Therapeutics Inc earned $-1.45 per diluted share (EPS) in fiscal year 2025. This represents an increase of 45.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$3.5M

YoY-9.3%

5Y CAGR+7.0%

10Y CAGR-17.0%

Relmada Therapeutics Inc held $3.5M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

73M

YoY+143.0%

5Y CAGR+35.0%

Relmada Therapeutics Inc had 73M shares outstanding in fiscal year 2025. This represents an increase of 143.0% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

0.0%

YoY+0.0pp

5Y CAGR+56.3pp

10Y CAGR+236.1pp

Relmada Therapeutics Inc's ROE was 0.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 0.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$26.9M

YoY-41.8%

5Y CAGR-5.7%

10Y CAGR+13.1%

Relmada Therapeutics Inc invested $26.9M in research and development in fiscal year 2025. This represents a decrease of 41.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

RLMD Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$26.9M-41.8%	$46.2M-15.7%	$54.8M-51.6%	$113.3M+25.1%	$90.6M+151.9%	$36.0M
SG&A Expenses	$32.2M-14.6%	$37.7M-22.9%	$48.9M+2.0%	$47.9M+36.6%	$35.1M+41.1%	$24.9M
Operating Income	-$59.1M+29.6%	-$83.9M+19.1%	-$103.7M+35.7%	-$161.2M-28.3%	-$125.7M-106.6%	-$60.8M
Interest Expense	N/A	N/A	$5.2M+93.7%	$2.7M+121.8%	$1.2M-14.3%	$1.4M
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	$0	$0	$0+100.0%	-$157.0M-24.9%	-$125.8M-111.5%	-$59.5M
EPS (Diluted)	$-1.45+45.3%	$-2.65+19.2%	$-3.28+38.1%	$-5.30+26.0%	$-7.16	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$8.1M	N/A	$4.0M+43.2%	$2.8M-76.4%	$12.0M	N/A	$11.1M+4.0%	$10.7M
SG&A Expenses	$11.4M	N/A	$6.3M-15.0%	$7.4M+18.1%	$6.3M	N/A	$11.9M+46.5%	$8.1M
Operating Income	-$19.5M	N/A	-$10.3M-1.0%	-$10.2M+43.9%	-$18.2M	N/A	-$23.0M-22.3%	-$18.8M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$19.1M	N/A	-$10.1M-2.3%	-$9.9M+43.8%	-$17.6M	N/A	-$21.7M-22.3%	-$17.8M
EPS (Diluted)	$-0.22	N/A	$-0.300.0%	$-0.30+48.3%	$-0.58	N/A	$-0.72-22.0%	$-0.59

RLMD Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$94.0M+105.2%	$45.8M-53.0%	$97.6M-36.2%	$152.9M-31.5%	$223.3M+89.0%	$118.2M
Current Assets	$94.0M+105.2%	$45.8M-53.0%	$97.5M-36.2%	$152.9M-31.5%	$223.3M+89.1%	$118.1M
Cash & Equivalents	$3.5M-9.3%	$3.9M-5.7%	$4.1M-24.2%	$5.4M-87.9%	$44.4M+1681.0%	$2.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$7.5M-27.2%	$10.3M-15.6%	$12.2M-2.2%	$12.5M-17.2%	$15.1M+19.5%	$12.6M
Current Liabilities	$6.4M-37.5%	$10.3M-15.6%	$12.2M-2.2%	$12.5M-17.2%	$15.1M+19.5%	$12.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$86.5M+143.5%	$35.5M-58.4%	$85.4M-39.2%	$140.4M-32.6%	$208.3M+97.3%	$105.6M
Retained Earnings	-$698.3M-9.0%	-$640.9M-14.3%	-$560.9M-21.4%	-$462.1M-51.5%	-$305.1M-70.1%	-$179.3M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$235.4M+150.4%	$94.0M+531.9%	$14.9M-29.6%	$21.1M-23.7%	$27.7M-39.6%	$45.8M-17.8%	$55.7M-21.5%	$71.0M
Current Assets	$235.3M+150.4%	$94.0M+532.7%	$14.9M-29.6%	$21.1M-23.7%	$27.7M-39.6%	$45.8M-17.8%	$55.7M-21.5%	$71.0M
Cash & Equivalents	$9.8M+179.6%	$3.5M+152.6%	$1.4M+2.3%	$1.4M+17.7%	$1.1M-70.2%	$3.9M+159.9%	$1.5M-28.9%	$2.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$16.6M+122.0%	$7.5M+38.5%	$5.4M+4.7%	$5.2M-1.4%	$5.2M-49.1%	$10.3M+27.1%	$8.1M-15.1%	$9.5M
Current Liabilities	$12.9M+100.5%	$6.4M+23.9%	$5.2M+1.1%	$5.1M-1.9%	$5.2M-49.2%	$10.3M+27.3%	$8.1M-15.2%	$9.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$218.7M+152.8%	$86.5M+814.0%	$9.5M-40.7%	$15.9M-28.9%	$22.4M-36.8%	$35.5M-25.4%	$47.6M-22.6%	$61.5M
Retained Earnings	-$717.3M-2.7%	-$698.3M-2.9%	-$678.4M-1.5%	-$668.3M-1.5%	-$658.4M-2.7%	-$640.9M-3.0%	-$622.2M-3.6%	-$600.5M

RLMD Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$45.8M+11.5%	-$51.8M-0.2%	-$51.7M+50.2%	-$103.8M-13.0%	-$91.9M-230.4%	-$27.8M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	$182.1M
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	-$209.9M
Investing Cash Flow	-$48.1M-193.4%	$51.6M+2.2%	$50.5M+155.7%	$19.7M+136.5%	-$54.1M-57.1%	-$34.4M
Financing Cash Flow	$93.6M+232034.8%	-$40K+59.0%	-$98K-100.2%	$45.0M-76.0%	$187.9M+560.1%	$28.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$15.1M-3.2%	-$14.6M-117.1%	-$6.7M-5.0%	-$6.4M+64.6%	-$18.1M-105.3%	-$8.8M+47.2%	-$16.7M-25.6%	-$13.3M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$135.2M-75.8%	-$76.9M-1239.2%	$6.8M+1.1%	$6.7M-56.5%	$15.4M+35.4%	$11.3M-29.7%	$16.1M+15.2%	$14.0M
Financing Cash Flow	$156.6M+67.2%	$93.6M	$0	N/A	N/A	-$172K-92.5%	-$90K	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$3.4M	N/A	N/A	N/A	N/A	N/A	N/A	N/A

RLMD Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	0.0%0.0pp	0.0%0.0pp	0.0%+111.8pp	-111.8%-51.5pp	-60.4%-4.1pp	-56.3%
Return on Assets	0.0%0.0pp	0.0%0.0pp	0.0%+102.7pp	-102.7%-46.4pp	-56.3%-6.0pp	-50.3%
Current Ratio	14.62+10.2	4.45-3.5	8.00-4.3	12.26-2.6	14.83+5.5	9.37
Debt-to-Equity	0.09-0.2	0.29+0.1	0.14+0.1	0.09+0.0	0.07-0.0	0.12
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-8.7%	N/A	-106.6%-44.8pp	-61.9%+16.4pp	-78.3%	N/A	-45.6%-16.7pp	-28.9%
Return on Assets	-8.1%	N/A	-67.8%-21.1pp	-46.7%+16.7pp	-63.4%	N/A	-39.0%-14.0pp	-25.0%
Current Ratio	18.26+3.6	14.62+11.8	2.86-1.2	4.11-1.2	5.29+0.8	4.45-2.4	6.89-0.6	7.44
Debt-to-Equity	0.08-0.0	0.09-0.5	0.57+0.2	0.32+0.1	0.23-0.1	0.29+0.1	0.17+0.0	0.16
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Vtv Therapeutics VTVT

$132.8M

Serina Therapeutics SER

$27.0M

Actinium Pharmac ATNM

$37.0M

Veru VERU

$37.4M

Fibrogen Inc FGEN

$39.3M

Frequently Asked Questions

Is Relmada Therapeutics Inc profitable?

No, Relmada Therapeutics Inc (RLMD) reported a net income of $0 in fiscal year 2025.

What is Relmada Therapeutics Inc's return on equity (ROE)?

Relmada Therapeutics Inc (RLMD) has a return on equity of 0.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Relmada Therapeutics Inc's operating cash flow?

Relmada Therapeutics Inc (RLMD) generated -$45.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Relmada Therapeutics Inc's total assets?

Relmada Therapeutics Inc (RLMD) had $94.0M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Relmada Therapeutics Inc spend on research and development?

Relmada Therapeutics Inc (RLMD) invested $26.9M in research and development during fiscal year 2025.

How many shares does Relmada Therapeutics Inc have outstanding?

Relmada Therapeutics Inc (RLMD) had 73M shares outstanding as of fiscal year 2025.

What is Relmada Therapeutics Inc's current ratio?

Relmada Therapeutics Inc (RLMD) had a current ratio of 14.62 as of fiscal year 2025, which is generally considered healthy.

What is Relmada Therapeutics Inc's debt-to-equity ratio?

Relmada Therapeutics Inc (RLMD) had a debt-to-equity ratio of 0.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Relmada Therapeutics Inc's return on assets (ROA)?

Relmada Therapeutics Inc (RLMD) had a return on assets of 0.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Relmada Therapeutics Inc's cash runway?

Based on fiscal year 2025 data, Relmada Therapeutics Inc (RLMD) had $3.5M in cash against an annual operating cash burn of $45.8M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Relmada Therapeutics Inc's Piotroski F-Score?

Relmada Therapeutics Inc (RLMD) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

How financially healthy is Relmada Therapeutics Inc?

Relmada Therapeutics Inc (RLMD) scores 35 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.